Preferential Induction of CYP1A1 over CYP1B1 in Human Breast Cancer MCF-7 Cells after Exposure to Berberine

Chun-Jie Wen¹, Lan-Xiang Wu¹, Li-Juan Fu¹, Dong-Ya Shen¹, Xue Zhang¹, Yi-Wen Zhang², Jing Yu², Hong-Hao Zhou¹*

Abstract

Estrogens are considered the major breast cancer risk factor, and the carcinogenic potential of estrogens might be attributed to DNA modification caused by derivatives formed during metabolism. 17β-estradiol (E₂), the main steroidal estrogen present in women, is metabolized via two major pathways: formation of 2-hydroxyestradiol (2-OH E₂) and 4-hydroxyestradiol (4-OH E₂) through the action of cytochrome P450 (CYP) 1A1 and 1B1, respectively. Previous reports suggested that 2-OH E₂ has putative protective effects, while 4-OH E₂ is genotoxic and has potent carcinogenic activity. Thus, the ratio of 2-OH E₂/4-OH E₂ is a critical determinant of the toxicity of E₂ in mammary cells. In the present study, we investigated the effects of berberine on the expression profile of the estrogen metabolizing enzymes CYP1A1 and CYP1B1 in breast cancer MCF-7 cells. Berberine treatment produced significant induction of both forms at the level of mRNA expression, but with increased doses produced 16- to 52-fold greater induction of CYP1A1 mRNA over CYP1B1 mRNA. Furthermore, berberine dramatically increased CYP1A1 protein levels but did not influence CYP1B1 protein levels in MCF-7 cells. In conclusion, we present the first report to show that berberine may provide protection against breast cancer by altering the ratio of CYP1A1/CYP1B1, could redirect E₂ metabolism in a more protective pathway in breast cancer MCF-7 cells.

Keywords: Berberine - CYP1A1 - CYP1B1 - estrogen metabolism - MCF-7 breast cancer cells

Asian Pac J Cancer Prev, 15 (1), 495-499

Introduction

Breast cancer is one of the most common malignancies and the leading cause of mortality in females worldwide (Jemal et al., 2011). Estrogens have been recognized as the prime risk factor for the development of breast cancer (Feigelson et al., 1996; Cavalieri et al., 1997). In 2001 the US government added steroidal estrogens to the list of known human carcinogens (Yager et al., 2006; Clemons et al., 2007). Excessive estrogen exposure can initiate cancer development and promote carcinogenesis by the reaction of their oxidation products with DNA (Cavalieri et al., 1997).

17β-estradiol (E₂), the main estrogen in the breast, can be metabolically transformed to 2-OH E₂ and 4-OH E₂ (Parl et al., 2009). The catechols 2-OH E₂ and 4-OH E₂ can be oxidized to quinones (Cavalieri et al., 1997). Quinones derived from 2-OH E₂ (E₂-2,3-Q) do not seem to generate mutations (Cavalieri et al., 2000), moreover, 2-OH E₂ have putative protective effects via its 2-methoxy form (Zhu et al., 1998). In contrast, quinones derived from 4-OH E₂ (E₂-3,4-Q) is likely to have genotoxic and carcinogenic effects, which can react with DNA via its quinone to form predominantly depurinating and stable adducts (Cavalieri et al., 1997). Thus, this 4-OH E₂ appears to be one of the most genotoxic metabolites of E₂ in the breast epithelium (Liehr et al., 1996). It is critical to note that the ratio 2-OH E₂/4-OH E₂ could be a critical parameter of the carcinogenicity of E₂.

In breast epithelium, the production of estrogen catechols depends on the activity of enzymes, especially CYP1A1 and CYP1B1 (Badawi et al., 2001; Parl et al., 2009). CYP1A1 displays hydroxylase activity at the C2 position to form 2-OH E₂ metabolite, whereas CYP1B1 displays its primarily activity on the C4 position to produce 4-OH E₂ metabolite (Spink et al., 1992; Hayes et al., 1996). As in the case of the catechol ratio, the relative expression of these genes and the CYP1A1/CYP1B1 ratio could be critical in terms of carcinogenesis.

An understanding of the pathways in which natural compounds alter estrogen metabolism is a key step in the development of new breast cancer prevention strategies (Sarah et al., 2008). Dietary or pharmaceutical agents that can reduce the production of genotoxic estrogen metabolites may be effective in preventing estrogen-induced breast carcinogenesis. For example, a compound that increases the formation of 2-OH E₂, catalyzed by CYP1A1 would reduce the level of 4-OH E₂ catalyzed...
by CYP1B1 and thereby lower the potential for DNA damage.

Many herbs have been reported to be chemopreventive ingredients that have a potential for inhibition or induction of cytochrome P450 enzymes. Berberine, an isoquinoline alkaloid, isolated from many kinds of medical herbs such as Coptis chinensis and berberis aristata, exerts a modulating role on the metabolism of drugs and xenobiotics by acting as inducers or inhibitors of CYPs. In human liver microsomes, berberine inhibits CYP2D6 and CYP3A4 activities, in mice, berberine inhibits CYP3A11 and CYP3A25 expression while induces CYP1A2 expression (Guo et al., 2011a; Guo et al., 2011b). In renal-transplant recipients, berberine was reported to markedly elevate the blood concentration of cyclosporine A, a drug metabolized by CYP3A4 (Wu et al., 2005). Prior to our work, little has been reported about the effects of berberine on estrogen-metabolizing enzymes CYP1A1 and CYP1B1 in human breast cells. Thus, in the current study we have investigated the effects of the berberine on the RNA and protein expression of the estrogen-metabolizing enzymes CYP1A1 and CYP1B1 using the human breast cancer cell line MCF-7.

Materials and Methods

Materials

Berberine (>95% of purity; Sigma, St. Louis, MO) was dissolved in dimethylsulfoxide (DMSO; Sigma). The final concentration of the vehicle was always less than 0.1%.

Cell culture

Human breast cancer cells MCF-7 were purchased from the American Type Culture Collection (ATCC; Manassas, VA). The cells were grown in RPMI 1640 medium (HyClone, South Logan, UT) with 10% fetal calf serum (FBS; HyClone), 100U/ml penicillin and 100μg/ml streptomycin. Cells were incubated at 37°C in a humidified atmosphere of 95% air and 5% CO₂. Cells were sub-cultured twice weekly. Berberine was used at 5, 10, 20 and 40μM dose. Cells were cultured for either 24, 48 and 72 h. All treatments were done in quadruplicate.

Real-time PCR

Total RNA from the treated and control cells were isolated by TriZol (Invitrogen Valenica, CA, USA) according to the manufacturer’s instructions. Sample (2μg) of RNA was reverse-transcribed using the RevertAid First Strand cDNA Synthesis Kit (Fermantas, St. Leon-Rot, Germany) to prepare first strand cDNA. qPCR amplification was carried out using SYBR-green detection method. Twenty micrograms total protein was resolved in 10% SDS-polyacrylamide gels and transferred to PVDF membranes (Immobilon P, Millipore, Bedford, MA) under standard conditions. After blocking with 5% skimmed milk, the membranes were probed with a 1:100 dilution primary antibody for CYP1A1 antibody H-70 (Santa Cruz, sc-20772) and CYP1B1 antibody H-105 (Santa Cruz, sc-32882) and a 1:5000 dilution primary β-actin antibody (sigma, A5441) for overnight at 4°C. Membranes were washed and then incubated with a 1:10000 dilution of DyLight 800-labeled second antibodies (KPL, Maryland, USA) for 1 h. The amount of immunoreactive production in each lane was determined using Odyssey Two-Color Infrared Imaging System (LI-COR Bioscience, St. Lincoln, NE, USA). Blots were reprobed with antibodyβ-actin protein to normalize the results.

Statistical analysis

The data were expressed as mean ± standard deviation. The results were analyzed using the one-way analysis of variance (ANOVA) test. The statistical significance between the experimental groups and their respective controls was assessed by Tukey’s post hoc test by using GraphPad Prism 4 software package (San Diego, CA, USA). A p value <0.05 was considered statistically significant.

Results

The effect of berberine on the expression of CYP1A1 in MCF-7 cells

Treatment of MCF-7 cells with increased doses of CYP1B1 (5’ CTA GGC AAA GGT CCC AGT TC 3’ and 5’ CAG CAC CGA CAG GAG TAG CA 3’), β-actin (5’ TTG CCG AGA TGC AGA AGG A 3’ and 5’ AGG TGG ACA CGG AGG CCA GGA T 3’).

Western Blot

The adherent cells were lysed in RIPA lysis buffer supplemented with proteinase inhibitors phenyl methyl sulfonyl fluoride (PMSF), and incubated on ice for 30 min. Cell lysate was centrifuged at 14,000 rpm for 15 min and the supernatant was recovered. The protein concentration of the lysates was determined by BCA method. Twenty micrograms total protein was resolved in 10% SDS-polyacrylamide gels and transferred to PVDF membranes (Immobilon P, Millipore, Bedford, MA) under standard conditions. After blocking with 5% skimmed milk, the membranes were probed with a 1:100 dilution primary antibody for CYP1A1 antibody H-70 (Santa Cruz, sc-20772) and CYP1B1 antibody H-105 (Santa Cruz, sc-32882) and a 1:5000 dilution primary β-actin antibody (sigma, A5441) for overnight at 4°C. Membranes were washed and then incubated with a 1:10000 dilution of DyLight 800-labeled second antibodies (KPL, Maryland, USA) for 1 h. The amount of immunoreactive production in each lane was determined using Odyssey Two-Color Infrared Imaging System (LI-COR Bioscience, St. Lincoln, NE, USA). Blots were reprobed with antibodyβ-actin protein to normalize the results.

Figure 1. Regulation of CYP1A1 mRNA Expression by Berberine. (A) MCF-7 cells were treated with increased concentrations of berberine (0, 5, 10, 20 and 40 μM) for 48 h. (B) MCF-7 cells were treated with 20 μM concentration of berberine for 24-72h. Total RNA was isolated using TRIzol reagent, and CYP1A1 mRNA was quantified by RT-PCR. Duplicate reactions were performed for each experiment, and the values are presented as mean ± SD. ***P<0.001 compared with the control group. BBR, berberine
Preferential Induction of CYP1A1 over CYP1B1 in Breast Cancer MCF-7 Cells after Exposure to Berberine

Table 1. Ratio of CYP1A1 to CYP1B1 mRNA Expression in Increased Doses of Berberine-treated MCF-7 Cells at the 48 h

<table>
<thead>
<tr>
<th>Dose (μM)</th>
<th>CYP1A1 fold change</th>
<th>CYP1B1 fold change</th>
<th>Ratio (CYP1A1/CYP1B1)</th>
</tr>
</thead>
<tbody>
<tr>
<td>5</td>
<td>147.61</td>
<td>9</td>
<td>16.4</td>
</tr>
<tr>
<td>10</td>
<td>195.38</td>
<td>9.24</td>
<td>21.1</td>
</tr>
<tr>
<td>20</td>
<td>301.89</td>
<td>7.14</td>
<td>42.3</td>
</tr>
<tr>
<td>40</td>
<td>489.78</td>
<td>9.3</td>
<td>52.7</td>
</tr>
</tbody>
</table>

Table 2. Ratio of CYP1A1 to CYP1B1 mRNA Expression in 20 μM Berberine-treated MCF-7 Cells Ranging from 24 to 72 h Time Point

<table>
<thead>
<tr>
<th>Time (h)</th>
<th>CYP1A1 fold change</th>
<th>CYP1B1 fold change</th>
<th>Ratio (CYP1A1/CYP1B1)</th>
</tr>
</thead>
<tbody>
<tr>
<td>24</td>
<td>194.92</td>
<td>7.86</td>
<td>24.8</td>
</tr>
<tr>
<td>48</td>
<td>414.35</td>
<td>8.6</td>
<td>48.2</td>
</tr>
<tr>
<td>72</td>
<td>594.97</td>
<td>25.24</td>
<td>23.6</td>
</tr>
</tbody>
</table>

Berberine treatment elevates the expression of CYP1A1 to significantly higher levels than CYP1B1 in MCF-7 cells

To compare the relationship between CYP1A1 and CYP1B1 mRNA expression in response to berberine exposure in MCF-7 cells, the ratios of CYP1A1 to...
CYP1B1 fold changes were calculated for each dose and time point. The ratios greater than one indicate that the expression of CYP1A1 was induced to a higher level than the expression of CYP1B1. As shown in Table 1, the treatment of MCF-7 cells with berberine in all doses resulted in the ratio of CYP1A1 to CYP1B1 greater than one. At all time points tested, 20 μM doses of berberine produce a ratio of CYP1A1 to CYP1B1 greater than one (Table 2). The highest ratios of CYP1A1 to CYP1B1 caused by 40 μM berberine at 48h and were equal to 52.7. According to the western blot analysis, berberine strikingly increases CYP1A1 but not CYP1B1 protein levels, indicating berberine preferential induction of CYP1A1 over CYP1B1 in MCF-7 cells.

Discussion

The prolonged exposure of estrogens is well known to play a role in breast cancer etiology (Feigelson et al., 1996; Cavalieri et al., 1997). Accumulative evidences suggest that estrogen-induced carcinogenesis depends on estrogen metabolism. Hydroxylation, which is the first step in the metabolism of estrogens, is initiated by CYP enzymes, especially CYP1A1 and CYP1B1 (Parl et al., 2009). CYP1A1 generates primarily 2-OH E2, which is less toxic and has been considered as protective (Spink et al., 1992; Schumacher et al., 1999). However, CYP1B1 displays its primary activity on the C4 position to produce 4-OH E2 (Hayes et al., 1996). Additionally, 4-OH E2 generates free radicals with corresponding semiquinone and quinone forms, which cause depurinating adducts and readily lead to mutation events (Cavalieri et al., 1997; Parl et al., 2009). In various studies, the ratio of 2-OH E2/4-OH E2 has been shown to be a cancer marker. The relative activities of CYP1A1 and CYP1B1 are critical determinants of this ratio. Evidence from previous studies suggests that exposure to exogenous compounds alter the pathways of estrogen metabolism by modulating CYP1A1 and CYP1B1 in vivo and in vitro. The current study was conducted to assess the effects of berberine on the expression of estrogen-metabolizing enzymes CYP1A1 and CYP1B1.

Berberine, one of the major alkaloids, has been shown to possess anti-cancer activity including inhibition of protein synthesis, cell cycle progression and apoptosis in breast cancer cells. In the present study, we set out to explain the alternative mechanisms by which berberine may exert its anti-cancer effects. We found that berberine treatment produced greater inductions of the expression of CYP1A1 gene over CYP1B1 gene. Results from this study suggests that berberine, may shift expression of estrogen-metabolizing enzymes CYP1A1 over CYP1B1.

The results of the present study showed also that berberine strongly induced CYP1B1 mRNA expression; however, the protein levels were unchanged in all cases. The lack of correlation between the CYP1B1 transcripts and protein levels was reported also in the previous studies (Sissung et al., 2006; Sarah et al., 2008; Szaefer et al., 2012). The difference between mRNA expression and the corresponding protein levels may indicate that the translation mechanism is saturated in the conditions of enhanced transcription. For example, quercetin treatment dramatically increased CYP1B1 mRNA levels but only slightly increased protein levels (Sarah et al., 2008). The transcripts of CYP1B1 were increased 11-fold after exposure to indole-3-carbinol, however, the protein levels were not changed (Szaefer et al., 2012). It is probably because that some posttranscriptional modifications such as proteolytic degradation can modulate CYP1B1 protein levels (Bandiera et al., 2005).

In the present study, we have reported that berberine differentially affects the expression of CYP1A1 and CYP1B1; this could be one possible mechanism by which the berberine exerts protective effects against estrogen-related breast carcinogenesis. Further studies are required to analyze the ratio of 2-OH E2/4-OH E2 following exposure to berberine by using high performance liquid chromatography (HPLC) analysis in vivo and in vitro, and the mechanisms of regulation of these genes by berberine also need to be further elucidated.

Acknowledgements

This research was supported by the National Science Foundation Research Grant of China (No.84402511), National Science Foundation of Chongqing (No. cstc2011jjA10004), Postdoctoral Science Foundation of China (No.2011M500669) and Special Postdoctoral Research Foundation of Chongqing (No.Yu xm201102007).

References


Preferential Induction of CYP1A1 over CYP1B1 in Breast Cancer MCF-7 Cells after Exposure to Berberine

DOI:http://dx.doi.org/10.7314/APJCP.2014.15.1.495